2015 Annual Meeting

Society of Cardiovascular Pathology

2015 Annual Meeting

Room CC 309, March 22 2015, 8:30am to 12:00pm

Joseph J. Maleszewski, Carmela Tan, James Stone, John Berk, Marc Semigran, Michael C. Fishbein

Recent Developments in the Diagnosis and Treatment of Amyloidosis

Educational Objective

Cardiovascular diseases remain a significant cause of morbidity and mortality in developed countries. The amyloidoses are an important group of systemic diseases that cause substantial cardiac impairment. Recently there have been advances in the manner in which these diseases are diagnosed, classified, and treated. Topics to be covered in this session included amyloid subtyping techniques including mass spectrometry, classification of the amyloidoses including new and rare forms of amyloid, the state of the art use of protein folding inhibitors to treat amyloidosis, and the results obtained from an a new international consortium for performing cardiac transplantation coupled with stem cell transplantation to treat immunoglobulin light chain amyloidosis. The session will be capped by Dr. Michael Fishbein, the recipient of the SCVP Distinguished Achievement Award, speaking on arteriosclerosis. In addition, there will be a portion of the session devoted to short presentations by a selected subset of young investigators who have submitted heart- and vessel-oriented posters to USCAP. This will provide an important opportunity to develop and build fellowship amongst junior and senior members of the USCAP with an interest in cardiovascular pathology. Moreover the brief presentations will allow for a fairer judging of posters being considered for award of the SCVP Young Investigator prize, with excellent feedback from an increased number of cardiovascular pathologists at the meeting. This activity has been designed to meet the educational needs of pathologists, clinicians, and other health care professionals who are involved in managing and treating patients with amyloidosis and other cardiovascular diseases as well as researchers who investigate the mechanisms of these diseases. Upon completion of this educational activity, participants should be able to:

  1. Describe the importance of amyloid subtyping in the management of patients with amyloidosis.
  2. Describe the rationale for using protein folding inhibitors to treat amyloidosis.
  3. Describe the impact of combined cardiac transplantation with autologous stem cell transplantation in patients with light chain amyloidosis.
  4. Describe the rationale and scientific support for our concepts of arteriosclerosis.

Session Credits: CME = 3 / SAMs = N/A


Companion Meeting Moderator
Speaker: James R. Stone, MD, PhD, Massachusetts General Hospital, Boston, MA
Handouts: View PDF
Companion Meeting Moderator
Speaker: Carmela D. Tan, MD, Cleveland Clinic, Cleveland, OH
Amyloidosis: Typing and Nomenclature
Speaker: Joseph J. Maleszewski, MD, Mayo Clinic, Rochester, MN
Handouts: View PDF
Evolving Therapies for Transthyretin Amyloidosis
Speaker: John L. Berk, MD, Boston University, Boston, MA
Handouts: View PDF
Outcomes from an International Registry of Cardiac Transplantation for Light Chain and Transthyretin Amyloidosis
Speaker: Marc J. Semigran, MD, Massachusetts General Hospital, Boston, MA
Handouts: View PDF
Young Investigator Presentations
Arteriosclerosis: Facts and Fancy
Speaker: Michael Fishbein, MD, University of California Los Angeles Medical Center, Los Angeles, CA Recipient of the Society of Cardiovascular Pathology Distinguished Achievement Award for 2015
Handouts: View PDF


view more